PLoS ONE (Jan 2015)

Fn14, a Downstream Target of the TGF-β Signaling Pathway, Regulates Fibroblast Activation.

  • Shaoxian Chen,
  • Juli Liu,
  • Min Yang,
  • Wen Lai,
  • Litong Ye,
  • Jing Chen,
  • Xinghua Hou,
  • Hong Ding,
  • Wenwei Zhang,
  • Yueheng Wu,
  • Xiaoying Liu,
  • Shufang Huang,
  • Xiyong Yu,
  • Dingzhang Xiao

DOI
https://doi.org/10.1371/journal.pone.0143802
Journal volume & issue
Vol. 10, no. 12
p. e0143802

Abstract

Read online

Fibrosis, the hallmark of human injuries and diseases such as serious burns, is characterized by excessive collagen synthesis and myofibroblast accumulation. Transforming growth factor-β (TGF-β), a potent inducer of collagen synthesis, has been implicated in fibrosis in animals. In addition to TGF-β, fibroblast growth factor-inducible molecule 14 (Fn14) has been reported to play an important role in fibrotic diseases, such as cardiac fibrosis. However, the function and detailed regulatory mechanism of Fn14 in fibrosis are unclear. Here, we investigated the effect of Fn14 on the activation of human dermal fibroblasts. In normal dermal fibroblasts, TGF-β signaling increased collagen production and Fn14 expression. Furthermore, Fn14 siRNA blocked extracellular matrix gene expression; even when TGF-β signaling was activated by TGF-β1, fibroblast activation remained blocked in the presence of Fn14 siRNA. Overexpressing Fn14 increased extracellular matrix gene expression. In determining the molecular regulatory mechanism, we discovered that SMAD4, an important TGF-β signaling co-mediator, bound to the Fn14 promoter and activated Fn14 transcription. Taken together, these results indicate that the TGF-β signaling pathway activates Fn14 expression through the transcription factor SMAD4 and that activated Fn14 expression increases extracellular matrix synthesis and fibroblast activation. Therefore, Fn14 may represent a promising approach to preventing the excessive accumulation of collagen or ECM in skin fibrosis.